Pipeline & Medicines Explore the Science of Possibility View Vertex Research Giving BackLearn more about our STEM Program, Volunteer Efforts, Grants and Funding./giving-back Recent UpdatesFDA Approves SYMDEKOExpanded EU Approval for ORKAMBIKALYDECO Approved for Additional Mutations The Stories Behind Vertex: × We Are Vertex Why Diversity Matters to Our Culture & Who We Want to Be We Are Vertex Science and Arts Educator Mary Brooks Joins the Learning Lab to Help Integrate Arts into STEM Education Science Vertex Initiates Second Phase 3 VX-659 Triple Combination Study in Certain People with Cystic Fibrosis We Are Vertex Voices From Clinical Development: How Compounds Discovered in the Lab Translate to a Clinical Setting × We Are Vertex Meet JJ Jackson, Case Manager of Guidance & Patient Support We Are Vertex How Diversity Is a Catalyst for Innovation Science Vertex Initiates First Phase 3 VX-659 Triple Combination Study in Certain People with Cystic Fibrosis All in for CF Claire Wineland Inspires People Living with CF and Other Difficult Diseases to Live Their Best Lives We Are Vertex Why Intern at Vertex? Hear From Our 2017 Summer Interns We Are Vertex Voices From Research: Hear Stories From Our Scientists Explore More Stories @vertexpharma
We Are Vertex Science and Arts Educator Mary Brooks Joins the Learning Lab to Help Integrate Arts into STEM Education
Science Vertex Initiates Second Phase 3 VX-659 Triple Combination Study in Certain People with Cystic Fibrosis
We Are Vertex Voices From Clinical Development: How Compounds Discovered in the Lab Translate to a Clinical Setting
Science Vertex Initiates First Phase 3 VX-659 Triple Combination Study in Certain People with Cystic Fibrosis
All in for CF Claire Wineland Inspires People Living with CF and Other Difficult Diseases to Live Their Best Lives
